The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 21, 2020
Filed:
Apr. 11, 2016
Applicant:
Sangamo Biosciences, Inc., Richmond, CA (US);
Inventors:
Michael C. Holmes, Richmond, CA (US);
Gary Ka Leong Lee, Richmond, CA (US);
Assignee:
Sangamo Therapeutics, Inc., Brisbane, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/861 (2006.01); C12N 5/10 (2006.01); C12N 15/52 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/86 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); C12N 5/0636 (2013.01); C12N 15/63 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2510/02 (2013.01); C12N 2710/10343 (2013.01);
Abstract
Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies.